--- title: 'Clinical Daily Summary: What Happened on October 31, 2026' headline: Life Biosciences reports early ER-100 update in three glaucoma patients description: The company reported possible vision improvement and no major safety concerns so far at the low dose. url: https://thebench.bio/news/clinical/2026-10-31 topic: clinical date: '2026-10-31' covers: - '2026-10-31' date_published: '2026-10-31T12:00:48Z' date_modified: '2026-10-31T12:00:48Z' tags: - Software sources: 1 publisher: TheBench.Bio --- # Clinical Daily Summary: What Happened on October 31, 2026 **Life Biosciences reports early ER-100 update in three glaucoma patients** The company reported possible vision improvement and no major safety concerns so far at the low dose. ## Today in brief Three glaucoma patients received low-dose ER-100, and Life Biosciences reported possible signs of improved vision and no major safety concerns so far. [1] ## Early ER-100 update ER-100 uses OSK factors in an attempt to address vision conditions. [1] The roundup’s author says the results are too early to support strong conclusions and raises concerns about possible risks from OSK. [1] ## Sources 1. [Weekly reads: ER-100 trial update, ND AG stem cell alert, autoimmune CAR-T hurdles, AI effects on biologists, No on Prop 38](), The Niche, 2026-10-31 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: